HSP90 inhibition acts synergistically with heat to induce a pro-immunogenic form of cell death in colon cancer cells

References

• World Health Organization, Global Cancer Observatory, Cancer Today, IARC 69372 Lyon CEDEX08 France; [cited 27 August 2021]. Avaialble from: https://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf
   Google Scholar
• ter Haar G. Therapeutic applications of ultrasound. Prog Biophys Mol Biol. 2007;93(1–3):111–129.
   PubMed Web of Science ®Google Scholar
• Meijerink MR, Puijk RS, van Tilborg AAJM, et al. Radiofrequency and microwave ablation compared to systemic chemotherapy and to partial hepatectomy in the treatment of colorectal liver metastases: a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2018;41(8):1189–1204.
   PubMed Web of Science ®Google Scholar
• Marqa MF, Colin P, Nevoux P, et al. Focal laser ablation of prostate cancer: numerical simulation of temperature and damage distribution. Biomed Eng Online. 2011;10:45.
   PubMed Web of Science ®Google Scholar
• Vogl TJ, Farshid P, Naguib NN, et al. Thermal ablation of liver metastases from colorectal cancer: radiofrequency, microwave and laser ablation therapies. Radiol Med. 2014;119(7):451–461.
   PubMed Web of Science ®Google Scholar
• Illing RO, Kennedy JE, Wu F, et al. The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a western population. Br J Cancer. 2005;93(8):890–895.
   PubMed Web of Science ®Google Scholar
• Serrone J, Kocaeli H, Douglas Mast T, et al. The potential applications of high-intensity focused ultrasound (HIFU) in vascular neurosurgery. J Clin Neurosci. 2012;19(2):214–221.
   PubMed Web of Science ®Google Scholar
• Aptel F, Lafon C. Therapeutic applications of ultrasound in ophthalmology. Int J Hyperthermia. 2012;28(4):405–418.
   PubMed Web of Science ®Google Scholar
• Leslie TA, Kennedy JE. High intensity focused ultrasound in the treatment of abdominal and gynaecological diseases. Int J Hyperthermia. 2007;23(2):173–182.
   PubMed Web of Science ®Google Scholar
• Van der Kooij SM, Ankum WM, Hehenkamp WJ. Review of nonsurgical/minimally invasive treatments for uterine fibroids. Curr Opin Obstet Gynecol. 2012;24(6):368–375.
   PubMed Web of Science ®Google Scholar
• Illing R, Chapman A. The clinical applications of high intensity focused ultrasound in the prostate. Int J Hyperthermia. 2007;23(2):183–191.
   PubMed Web of Science ®Google Scholar
• Barqawi AB, Crawford ED. Emerging role of HIFU as a noninvasive ablative method to treat localized prostate cancer. Oncology. 2008;22(2):123–129.
   PubMed Web of Science ®Google Scholar
• Li S, Wu PH. Magnetic resonance image-guided versus ultrasound-guided high-intensity focused ultrasound in the treatment of breast cancer. Chin J Cancer. 2013;32(8):441–452.
   PubMedGoogle Scholar
• Mearini L. High intensity focused ultrasound, liver disease and bridging therapy. World J Gastroenterol. 2013;19:7494–7499.
   PubMed Web of Science ®Google Scholar
• Zhou Y. High-intensity focused ultrasound treatment for advanced pancreatic cancer. Gastroenterol Res Pract. 2014;2014:205325.
   PubMed Web of Science ®Google Scholar
• Yarmolenko PS, Moon EJ, Landon C, et al. Thresholds for thermal damage to normal tissues: an update. Int J Hyperthermia. 2011;27(4):320–343.
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Viglianti BL, Lora-Michiels M, et al. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia. 2003;19(3):267–294.
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Abraham J, Viglianti B. Evolution of thermal dosimetry for application of hyperthermia to treat cancer. Adv Heat Transfer. 2015;47:397–421.
   Google Scholar
• Wu F. Heat-based tumor ablation: role of the immune response. Adv Exp Med Biol. 2016;880:131–153.
   PubMed Web of Science ®Google Scholar
• Garg AD, Dudek-Peric AM, Romano E, et al. Immunogenic cell death. Int J Dev Biol. 2015;59(1–3):131–140.
   PubMed Web of Science ®Google Scholar
• Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3(9):e955691.
   PubMed Web of Science ®Google Scholar
• Liu P, Zhao L, Kepp O, et al. Quantitation of calreticulin exposure associated with immunogenic cell death. Methods Enzymol. 2020;632:1–13.
   PubMed Web of Science ®Google Scholar
• Garg AD, Krysko DV, Verfaillie T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. Embo J. 2012;31(5):1062–1079.
   PubMed Web of Science ®Google Scholar
• Fredly H, Ersvaer E, Gjertsen B-T, et al. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncol Rep. 2011;25(6):1549–1556.
   PubMed Web of Science ®Google Scholar
• Uscanga-Palomeque AC, Calvillo-Rodríguez KM, Gómez-Morales L, et al. CD47 agonist peptide PKHB1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells. Cancer Sci. 2019;110(1):256–268.
   PubMed Web of Science ®Google Scholar
• Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2(63):63ra94.
   PubMed Web of Science ®Google Scholar
• Sapareto S, Dewey W. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984;10(6):787–800.
   PubMed Web of Science ®Google Scholar
• Sapareto SA. Thermal isoeffect dose: addressing the problem of thermotolerance. Int J Hyperthermia. 1987;3(4):297–305.
   PubMed Web of Science ®Google Scholar
• Mouratidis PXE, Rivens I, Civale J, et al. Relationship between thermal dose and cell death for "rapid" ablative and "slow" hyperthermic heating. Int J Hyperthermia. 2019;36(1):229–243.
   PubMed Web of Science ®Google Scholar
• Ananthan J, Goldberg AL, Voellmy R. Abnormal proteins serve as eukaryotic stress signals and trigger the activation of heat shock genes. Science. 1986;232(4749):522–524.
   PubMed Web of Science ®Google Scholar
• Henle KJ, Leeper DB. Modification of the heat response and thermotolerance by cycloheximide, hydroxyurea and lucanthone in CHO cells. Radiat Res. 1982;90(2):339–347.
   PubMed Web of Science ®Google Scholar
• Mizzen LA, Welch WJ. Characterization of the thermotolerant cell. I. Effects on protein synthesis activity and the regulation of heat-shock protein 70 expression. J Cell Biol. 1988;106(4):1105–1116.
   PubMed Web of Science ®Google Scholar
• Lepock JR. How do cells respond to their thermal environment? Int J Hyperthermia. 2005;21(8):681–687.
   PubMed Web of Science ®Google Scholar
• Burdon RH, Slater A, McMahon M, et al. Hyperthermia and the heat-shock proteins of HeLa cells. Br J Cancer. 1982;45(6):953–963.
   PubMed Web of Science ®Google Scholar
• Schumacher RJ, Hansen WJ, Freeman BC, et al. Cooperative action of Hsp70, Hsp90, and DnaJ proteins in protein renaturation . Biochemistry. 1996;35(47):14889–14898.
   PubMed Web of Science ®Google Scholar
• Prodromou C, Roe SM, O'Brien R, et al. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell. 1997;90(1):65–75.
   PubMed Web of Science ®Google Scholar
• Ritossa F. A new puffing pattern induced by temperature shock and DNP in drosophila. Experientia. 1962;18(12):571–573.
   Google Scholar
• Sreedhar AS, Kalmár E, Csermely P, et al. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 2004;562(1-3):11–15.
   PubMed Web of Science ®Google Scholar
• Wiech H, Buchner J, Zimmermann R, et al. Hsp90 chaperones protein folding in vitro. Nature. 1992;358(6382):169–170.
   PubMed Web of Science ®Google Scholar
• Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem. 2006;75:271–294.
   PubMed Web of Science ®Google Scholar
• Sawarkar R, Sievers C, Paro R. Hsp90 globally targets paused RNA polymerase to regulate gene expression in response to environmental stimuli. Cell. 2012;149(4):807–818.
   PubMed Web of Science ®Google Scholar
• Kubota H, Yamamoto S, Itoh E, et al. Increased expression of co-chaperone HOP with HSP90 and HSC70 and complex formation in human colonic carcinoma. Cell Stress Chaperones. 2010;15(6):1003–1011.
   PubMed Web of Science ®Google Scholar
• Barrott JJ, Haystead TA. Hsp90, an unlikely ally in the war on cancer. Febs J. 2013;280(6):1381–1396.
   PubMed Web of Science ®Google Scholar
• Song KH, Oh SJ, Kim S, et al. HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors. Nat Commun. 2020;11(1):562.
   PubMed Web of Science ®Google Scholar
• Huang Q, He S, Tian Y, et al. Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice. Blood. 2017;129(20):2737–2748.
   PubMed Web of Science ®Google Scholar
• Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol. 2005;23(18):4152–4161.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol. 2005;23(6):1078–1087.
   PubMed Web of Science ®Google Scholar
• Weigel BJ, Blaney SM, Reid JM, et al. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a children’s oncology group study. Clin Cancer Res. 2007;13(6):1789–1793.
   PubMed Web of Science ®Google Scholar
• Egorin MJ, Rosen DM, Wolff JH, et al. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res. 1998;58(11):2385–2396.
   PubMed Web of Science ®Google Scholar
• Kelland LR, Sharp SY, Rogers PM, et al. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst. 1999;91(22):1940–1949.
   PubMed Web of Science ®Google Scholar
• Meli M, Pennati M, Curto M, et al. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J Med Chem. 2006;49(26):7721–7730.
   PubMed Web of Science ®Google Scholar
• Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008;68(8):2850–2860.
   PubMed Web of Science ®Google Scholar
• Brough PA, Aherne W, Barril X, et al. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem. 2008;51(2):196–218.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Bauer TM, Lamar R, et al. A phase 2 study of the Hsp90 inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors. Cancer Invest. 2016;34(6):265–270.
   PubMed Web of Science ®Google Scholar
• Seggewiss-Bernhardt R, Bargou RC, Goh YT, et al. Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer. 2015;121(13):2185–2192.
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Costa DB, Oxnard GR, et al. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. Ann Oncol. 2018;29(10):2092–2097.
   PubMed Web of Science ®Google Scholar
• Miyagawa T, Saito H, Minamiya Y, et al. Inhibition of Hsp90 and 70 sensitizes melanoma cells to hyperthermia using ferromagnetic particles with a low curie temperature. Int J Clin Oncol. 2014;19(4):722–730.
   PubMed Web of Science ®Google Scholar
• Vriend LEM, van den Tempel N, Oei AL, et al. Boosting the effects of hyperthermia-based anticancer treatments by HSP90 inhibition. Oncotarget. 2017;8(57):97490–97503.
   PubMedGoogle Scholar
• Adkins I, Sadilkova L, Hradilova N, et al. Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells. Oncoimmunology. 2017;6(5):e1311433.
   PubMed Web of Science ®Google Scholar
• Mouratidis PX, Rivens I, Ter Haar G. A study of thermal dose-induced autophagy, apoptosis and necroptosis in colon cancer cells. Int J Hyperthermia. 2015;31(5):476–488.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446.
   PubMed Web of Science ®Google Scholar
• Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;461(7261):282–286.
   PubMed Web of Science ®Google Scholar
• Iyer SS, Pulskens WP, Sadler JJ, et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci USA. 2009;106(48):20388–20393.
   PubMed Web of Science ®Google Scholar
• Shevtsov M, Balogi Z, Khachatryan W, et al. Membrane-Associated heat shock proteins in oncology: from basic research to new theranostic targets. Cells. 2020;9(5):1263.
   Web of Science ®Google Scholar
• Luft JC, Benjamin IJ, Mestril R, et al. Heat shock factor 1-mediated thermotolerance prevents cell death and results in G2/M cell cycle arrest. Cell Stress Chaper. 2001;6(4):326–336.
   PubMed Web of Science ®Google Scholar
• Roti Roti JL, Kampinga HH, Malyapa RS, et al. Nuclear matrix as a target for hyperthermic killing of cancer cells. Cell Stress Chaper. 1998;3(4):245–255.
   PubMed Web of Science ®Google Scholar
• Breakstone R. Colon cancer and immunotherapy-can we go beyond microsatellite instability? Transl Gastroenterol Hepatol. 2021;6:12.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Rajput A, Jin N, et al. Mechanisms of immunosuppression in colorectal cancer. Cancers. 2020;12(12):3850.
   PubMed Web of Science ®Google Scholar
• Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins . Mol Cell Biol. 1999;19(8):5237–5246.
   PubMed Web of Science ®Google Scholar
• Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. Embo J. 2003;22(20):5551–5560.
   PubMed Web of Science ®Google Scholar
• Klune JR, Dhupar R, Cardinal J, et al. HMGB1: endogenous danger signaling. Mol Med. 2008;14(7–8):476–484.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860–875.
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–1059.
   PubMed Web of Science ®Google Scholar
• Jube S, Rivera ZS, Bianchi ME, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012;72(13):3290–3301.
   PubMed Web of Science ®Google Scholar
• Palumbo R, Sampaolesi M, De Marchis F, et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol. 2004;164(3):441–449.
   PubMed Web of Science ®Google Scholar
• Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405(6784):354–360.
   PubMed Web of Science ®Google Scholar
• Yang GL, Zhang LH, Bo JJ, et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol. 2012;106(1):57–61.
   PubMed Web of Science ®Google Scholar
• Chiba S, Baghdadi M, Akiba H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832–842.
   PubMed Web of Science ®Google Scholar
• Ueda M, Takahashi Y, Shinden Y, et al. Prognostic significance of high mobility group box 1 (HMGB1) expression in patients with colorectal cancer. Anticancer Res. 2014;34(10):5357–5362.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang M, Zhou L, et al. Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. J Exp Clin Cancer Res. 2015;34(1):51.
   PubMedGoogle Scholar
• Huang M, Geng Y, Deng Q, et al. Translationally controlled tumor protein affects colorectal cancer metastasis through the high mobility group box 1-dependent pathway. Int J Oncol. 2018;53(4):1481–1492.
   PubMed Web of Science ®Google Scholar
• Li W, Wu K, Zhao E, et al. HMGB1 recruits myeloid derived suppressor cells to promote peritoneal dissemination of Colon cancer after resection. Biochem Biophys Res Commun. 2013;436(2):156–161.
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191–195.
   PubMed Web of Science ®Google Scholar
• Youn JH, Shin JS. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol. 2006;177(11):7889–7897.
   PubMed Web of Science ®Google Scholar
• Calderwood SK, Theriault JR, Gong J. Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur J Immunol. 2005;35(9):2518–2527.
   PubMed Web of Science ®Google Scholar
• Qu S, Worlikar T, Felsted AE, et al. Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy. J Immunother Cancer. 2020;8(1):e000200.
   PubMed Web of Science ®Google Scholar
• Fite BZ, Wang J, Kare AJ, et al. Immune modulation resulting from MR-guided high intensity focused ultrasound in a model of murine breast cancer. Sci Rep. 2021;11(1):927.
   PubMed Web of Science ®Google Scholar